Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
Quick Takeaways: Why It Matters? Data for LPT‑CBD strengthens the scientific case for long‑acting, injectable CBD as a legitimate chronic pain option, not just a wellness supplement, which can increase veterinarian openness to cannabinoid-based therapies. The sustaine...
